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MicroRNA participates in multiple biological activities by combining with target genes, degrading target mRNA 
or suppressing its translation which regulates the expression of genes. MicroRNA-195 is an important member 
of microRNA-15/161/195/424/497 family. miRNA-195 exerts its significant biological function in regulating cell 
cycle, apoptosis, cell metabolism, cell proliferation and metastasis by targetedly modulating MYB, CCND1, 
CCND3, CCNE1, E2F3, CDK6, Bcl-2, APP, BACE1, GLUT, SRC-3, Vav2, and CDC42. Furthermore, 
miRNA-195 can regulate angiogenic factors such as FGF1, VEGF and signaling pathways such as TGF-β1/ 
Smads and participate in the restoration of intima, progress of tumour, and the remodling of angiocarpy. 
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Introduction 
MicroRNA (miRNA), consisting of 21~23 nucleotides, is 
a kind of noncoding, single stranded RNA molecules. 
Usually, it combines with the site in the 3’ untranslated 
region (UTR) and mediates the cleavage or the suppression 
of translation of the target mRNA [1]. A single miRNA is 
capable of regulating thousands of target genes 
simultaneously, thus widely participating in various 
physiological and pathological process such as embryonic 
development, cell proliferation, differentiation and apoptosis, 
substance metabolism, wound healing, the occurence and 
development of tumour [2].
Angiogenesis refers to the process, during which the 
original vessels produce new vessels by the proliferation and 
differentiation of endothelial cells in or not in the form of 
blastogenesis. This process is regulated by both angiogenic 
factors and antiangiogenic factors [3]. Recent studies have 
found that miRNA plays a key role in the physiological and 
pathological process closely related to angiogenesis such as 
wound healing, tumour, and scar proliferation. There have 
already been studies indicating that miRNA-195 affects 
angiogenesis and participates in the occurence and 
development of maglinancies and the remodeling of heart by 
regulating the signaling pathway in which the target genes 
are involved. This article is an overview about the biological 
function of miRNA-195 and its role in angiogenesis. 
The introduction to miRNA-195 
Lagos-Quintana [4] is the first to have discovered that the 
sequence of miRNA-195 exists on mice genes. Subsequently, 
by using homologous sequence prediction, Landgraf [5] has 
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demonstrated that miRNA-195 exists on human genes as 
well. The genes of has-miRNA-195 has been found to be 
located at the region of 17p13.1 on the chromosome by 
Flavin [6]. The mature sequence of miRNA-195 is 
UAGCAGCACCAHAAAUAUUGGC, which belongs to 
miRNA-15/16/195/497 family and possesses the same 5’ 
core sequence as mi-RNA-15, miRNA-16, miRNA-497: 
CGACGA[7]. miRNA-15A/16-1, miRNA-15b/16-2, 
miRNA-195/497 are respectively located at the region of 
13p14.3, 3q26.1 and 17p13.1 in the form of gene clusters[8]. 
The mechanism of action of miRNA-195 
MiRNA-195 exerts its function by base-pairing with the 
silence complex and combining with the target mRNA, thus 
regulating the expression of the target mRNA and protein. In 
recent years, Bioinformatics and experimental studies have 
found that miRNA-195 exerts its biological function of 
regulating cell cycle, apoptosis, cell metabolism, cell 
proliferation and metastasis by targetedly regulating MYB, 
CCND1, CCND3, CCNE1, E2F3, CDK6, Bcl-2, APP, 
BACE1, GLUT, SRC-3, Vav2, CDC42, and FAFN. 
MiRNA-195 inhibits cell cycle 
Cell cycle is the process during which a series of 
biochemistry reactions and structural changes take place and 
cell growth and proliferation are achieved. This process is 
mainly regulated by cell cycle regulatory protein. Cell cycle 
regulatory protein includes cell cycle protein, CDK, CDKI. 
MYB transcription factor family, which plays an important 
role in the regulation of cell cycle, is a kind of transcription 
factors containing MYB domain. Studies have discovered 
that miRNA-195 can act on 3’ untranslated region of MYB 
miRN-A and inhibits the expression of MYB miRNA so that 
cell proliferation is reduced [9]. Furthermore, miRNA-195 
down-regulates the expression of CCND1, CCND3, CCNE1, 
and E2F3 by acting on 3’UTR region of miRNA which codes 
for CCN1, CCN3, CCNE1, E2F3, blocking the G1/S 
transition[10-14]. Additionally, Deng [15] has suggested that 
gastric carcinoma cells of MGC-803, AGS, are respectively 
blocked by miRNA-195 at G0/G1, G2/M of cell cycle. 
Further studies have discovered that miRNA-195 suppresses 
the expression of CDK6 targetedly and inhibits the 
progression of cell cycle. 
MiRNA-195 regulates apoptosis 
Apoptosis is the natural death of cells, controlled by a 
series of genes and is regulated by the internal and external 
environment. Apoptosis is a significant balance factor in cell 
proliferation, differentiation and various pathologicial 
processes. miRNA-195 participates in multiple intracellular 
processes that promotes apoptosis. Latest studies have shown 
that the overexpression of miRNA-195 in hESC-NPCs has 
induced a number of cells to apoptosis [16]. The mechanism is 
that miRNA-195 regulates the small molecule GTP binding 
protein ARL2, which leads to apoptosis. The reduction of the 
number of cells caused by the overexpression of miRNA-195 
is antagonized by the overexpression of ARL2. Qu [17] has 
explored the function of miRNA in colon cancer cells and its 
adriamycin-resistant strains. The substantial down-regulation 
of the expression of miRNA-195 has been verified in 
HT29/DOX and LOVO/DOX drug-resistant strains of colon 
cancer by using miRNA microarray and PT-PCR. 
Drug-resistant strains which overexpress miRNA-195 are 
more sensitive to adri-amycin and more susceptible to 
apoptosis. miRNA-195 acts on 3’UTR region of 
Bcl-2mi-RNA, especially the first combing site of it. The 
suppression of the expression of Bcl-2L2 has been shown to 
promote apoptosis by further studies. Chen [18] has also 
discovered that miRNA-195 contributes to the 
down-regulation of Bcl-2, thus promoting apoptosis and 
participating in the progression of diabetic renal damage. 
Zhu [19] has disclosed that the apoptosis of myocardial cell is 
promoted when miRNA-195 down-regulates Sirt1, ROS. He 
[20] has also disclosed that miRNA-195 affects the apoptosis 
of neurons and participates in the pathogenesis of Alzheimer 
Disease. miRNA-195 has been demonstrated to act on 
various target genes and to regulate the apoptosis of multiple 
kinds of cells. 
MiRNA-195 inhibits cell metabolism 
Substance metabolism and energy metabolism are 
included in cell metabolism. Energy metabolism occurs 
together with substance metabolism and takes substance 
metabolism as its vector. Biological activities are based on 
cell metabolism. miRNA-195 has already been verified to 
play a significant role in the metabolism of glucose, lipids 
and protein. GLUT, which plays a part in transporting 
glucose into tissues and cells, is a kind of carrier protein, 
inserted in cell membrane. GLUT3 is characterized by its 
low value of Km, indicating that GLUT3 possesses great 
affinity to glucose and a higher efficiency in delivering than 
other carrier proteins. Therefore, the cells, at which GLUT3 
is located, are characterized to metabolize vigorously. Fei [21] 
has discovered the high expression of GLUT3 in T24 of 
human bladder cancer cells. It has been revealed that 
miRNA-195-5p targetedly suppresses the expression of 
GLUT3 in T24 cells, thereby reducing the glucose delivering 
in human bladder cancer cells and affecting cell growth. 
FASN is the key enzyme to catalyze the synthesis of 
endogenous long-chain fatty acids and the key factor to 
participate in lipids metabolism. Mao [22] has disclosed that 
miRNA-195 is capable of down-regulating the expression of 
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fatty acid synthase, therefore inhibiting the metastasis of 
osteosarcoma cells. 
MiRNA-195 inhibits cell proliferation and migration 
The biological activities of cells are importantly 
characterized by cell proliferation, which is the process of 
cell growth and splitting thus increasing the number of cells. 
To make up for the senescent and dead cells, the process of 
proliferation during which new cells are produced, is still 
needed after the organism has become mature. Cell migration 
refers to cells’ movement after receiving migratory signals 
and plays an important part in embryogenesis, cell foraging, 
wound healing, immunization, infection and the metastasis of 
cancer.miRNA-195 has been proved by several studies to 
inhibit cell proliferation and migration. SR-C-3 up-regulates 
and promotes the proliferation of cancer cells during the 
occurrence of human tumours (breast cancer, lung cancer, 
prostatic cancer). In liver cancer cells, miRNA-195 
down-regulates the expression of SRC-3 protein by 
combining with 3’ UTR region of SRC-3 gene, therefore 
inhibiting cell proliferation [23]. Vav2, a kind of important 
intracellular signal transduction protein, plays a key role in 
the formation of flat pseudopodia and cell migration. Vav2 is 
also the activator of Rho/Rac metabolism pathway which 
regulates blood pressure. This pathway modulates the 
cytoskeleton of vascular smooth muscle cells to promote 
vasoconstriction. Studies [24] have shown that the expression 
of migratory factors, Vav2 and CDC42 can be 
down-regulated by miRNA-195. After the silence of 
miRNA-195 is induced, the expression of Vav2 and CDC42 
has increased, thus stimulating the signal of 
V-av2/Rac1/CDC42 and the formation of lamellipodia, 
which promotes cell migration. 
MiRNA-195 regulates angiogenesis  
The introduction to angiogenesis 
Angiogenesis refers to the process, during which the 
original vessels produce new vessels by the proliferation and 
differentiation of endothelial cells in or not in the form of 
blastogenesis [3]. This process begins with cell chemotaxis, 
migration, proliferation and tube formation. Then vasular 
smooth muscle cells move into and adhere to the intima, 
which forms the complete vascular wall. Finally, the 
newborn vessel develops into mature vascular system by 
remodeling. Angiogenesis participates in the pathological 
process of periodical change in endometrium, embryogenesis, 
wound healing, diabetic retinopathy, diabetic feet, and 
maglinancies. Both proangiogenic factors and angiogenesis 
inhibitors regulate angiogenesis. VEGF, FGF, TGF-β, IL-8, 
Epo, heparanase, PD-ECGF, OPN, COX-2, Angs, TNF-α, 
HIF, LN, PLGF, Survivin and some adherence factors are 
proangiogenic factors. ENS and angiostatin are angiogenesis 
inhibitors [25]. Angiogenesis is regulated when miRNA-195 
promotes or inhibits the expression and the activities of these 
cytokines. 
MiRNA-195 affects angiogenesis by regulating cytokines 
MiRNA-195 participates in various physiological 
processes related to angiogenesis and development of 
different diseases. For instance, miRNA-195 regulates the 
phenotype of vascular smooth muscle cell and prevents 
neointimal formation [26]. miRNA-195 suppresses 
angiogenesis of Hepatocellular carcinoma by inhibiting the 
expression of VEGF [24]. miRNA-195 up-regulates 
TGF-β1/Smads Signalling Pathway, promoting cardiac 
remodeling [27]. 
MiRNA-195 and FGF1 
Fibroblast growth factor1 (FGF1) is one of the important 
factors which promotes angiogenesis. With stronger 
chemotaxis and an effect on promoting proliferation, it can 
promote the proliferation and migration of smooth muscle 
cells [28]. Wang [26] found that miRNA-195 expression was 
down-regulated when vascular smooth muscle cells were 
treated with oxidized low-density lipoprotein. They showed 
that the miRNA-195 could downregulate the expression level 
of Cdc42 and FGF1, inhibiting VSMCs proliferation and 
migration. Animal experiments confirmed that the 
miRNA-195 reduced neointimal formation in a 
balloon-injured carotid artery, indicating that miRNA-195 
played an important role in cardiovascular disease. Further 
studies showed that miRNA-195 reduced the expression of 
Cdc42 by combining with 3’UTR region of miRNA. Cdc42 
serves as an upstream signal to activate the downstream 
FGF1, reducing the formation of intima. 
The relationship between miRNA-195 and VEGF 
VEGF, which activates ERK and promotes angiogenesis 
by combining with VEGFR, is the most powerful 
proangiogenic factor that has so far been discovered. The 
expression of VEGF is increased in tumour cells or under the 
condition of anoxia, thus promoting angiogenesis. By using 
double luciferase test, researchers [24] have revealed that 
miRNA-195 can combine with 3’ UTR region of VEGF. In 
vitro tests have further confirmed that the overexpression of 
miRNA-195 restrains the expression of VEGF and 
down-regulates VEGF/VEGFR signal pathway, thus 
modulating angiogenesis negatively. 
The relationship between miRNA-195 and TGF-β 
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TGF-β is a kind of multi-functional cytokine, of which 
there are 2 kinds of receptors, type I and type II. AIK is the 
type I receptor of TGF-β. Smad which participates in the 
signal tranduction of TGF-β, is the cytoplasm 
neurotransmitter of TGF-β. Alk1 and Alk5 are two different 
kinds of type I receptor and participate in the regulation of 
angiogenesis through the signal pathway of TGF-β/Smads. 
After combining with its receptor, Alk1 makes Smad1/5/8 
phosphorylated and induces the endothelial cells to 
proliferate and migrate, therefore participating in 
angiogenesis [29]. Smad2/3 is activated when Alk5 combines 
with its receptor and antagonizes the function of Alk1 signal 
pathway, thus inhibiting cell proliferation and the formation 
of network, tubular vessels and inducing apoptosis [30]. Wang 
[27] holds the idea that miRNA-195 promotes the remodeling 
of heart by up-regulating TGF-β/Smads signal pathway. 
However, the specific target of miRNA-195 remains unclear 
and needs to be further experimentally studied. 
Summary and Prospect 
On one hand, angiogenesis promotes the physiological 
process of embryogenesis, the remodeling of endometrium, 
wound healing. On the other hand, angiogenesis plays a key 
role in the development of diseases such as scar proliferation, 
malignancies, diabetic retinopathy. Thereby, it is of great 
significance to further study the mechanism of angiogenesis 
and to provide novel therapeutic targets for promoting or 
inhibiting angiogenensis. miRNA-195 regulates the 
translation of multiple target genes and the expression of 
various kinds of proteins, thus participating in the regulation 
of cell cycle, apoptosis, cell metabolism, cell proliferation 
and migration. It has been disclosed by recent studies that 
miRNA-195 is closely associated with the regulation of 
angiogenesis, indicating that miRNA-195 is likely to be the 
therapeutic target for promoting or inhibiting angiogenesis. 
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